Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

GSK, Sanofi Surge as US Judge Dismisses Zantac Cases (2)

Dec. 7, 2022, 9:24 AM

GSK Plc and Sanofi surged after a US judge rejected the scientific evidence behind claims heartburn drug Zantac can cause cancer, meaning the drugmakers don’t have to face more than 5,000 lawsuits.

GSK shares rose 16% in London trading and Sanofi gained 8.8% in Paris. The UK drugmaker welcomed the dismissal, saying the ruling slapped down “unreliable and litigation-driven science.”

District Judge Robin Rosenberg in West Palm Beach, Florida, concluded that consumers used flawed science to back up lawsuits filed in federal court blaming Zantac for causing a variety of cancers. Rosenberg on Tuesday found plaintiffs’ experts couldn’t show legitimate ...